title: [Clinical cases of acquired coagulation inhibitors].
abstract: The acquired coagulation factor inhibitors are classified into alloantibodies, which appear in association with supplementary treatment for congenital coagulation factor deficiency, and autoantibodies, which are spontaneously produced. We report here 2 cases of acquired factor VIII inhibitor and 1 case of factor V inhibitor. Case 1: A 52-year-old woman noted swelling of the right parotid region in March 1988. Though contrast examination was scheduled, she was admitted for detailed examination due to a markedly prolonged coagulation time. An APTT correction test suggested that decreased factor VIII activity was due to the presence of an inhibitor. Since antinuclear antibody and SS-A antibody were positive and infiltration by lymphocytes in the salivary gland acini in a lip biopsy specimen was detected, Sjögren's syndrome was diagnosed. Case 2: A 33-year-old woman had normal delivery of her second child in February 1998. In June 1998, she suffered slight contusion in the left lower limb. The affected site became swollen and painful, making walking difficult. Since both upper limbs became markedly swollen after 1 week, she visited our hospital. Prolonged APTT and a marked decrease in factor VIII activity were observed. Factor VIII inhibitor titer was high at 19 Bethesda units. Case 3: A 64-year-old man had had asymptomatic macroscopic hematuria since the beginning of August 1998 but was placed under observation since no abnormal findings were observed on various imaging tests. However, he was admitted to Osaka City General Medical Center because of vesicular tamponade. Factor V activity was markedly decreased to 1.0%. PT correction test suggested that decreased factor V activity was due to the presence of an inhibitor. The underlying disease could not be determined in this case. In patients with acquired coagulation inhibitors, bleeding symptoms are reported to be mild in many cases, and severe bleeding is rare. However, cases of death without severe bleeding or underlying disease have also been reported, indicating that the prompt diagnosis and treatment of this condition are necessary.
authors.affiliation: Department of Clinical Hematology, Osaka City University, Osaka 545-8585.
authors.forename: T
authors.initials: T
authors.lastname: Yamane
authors.forename: M
authors.initials: M
authors.lastname: Hino
authors.forename: K
authors.initials: K
authors.lastname: Ota
authors.forename: M
authors.initials: M
authors.lastname: Akahori
authors.forename: M
authors.initials: M
authors.lastname: Hirai
authors.forename: T
authors.initials: T
authors.lastname: Inoue
authors.forename: A
authors.initials: A
authors.lastname: Mugitani
authors.forename: N
authors.initials: N
authors.lastname: Tatsumi
mesh_terms: D000328:Adult; D001323:Autoantibodies / Q000097:blood; D019774:Blood Coagulation Factor Inhibitors / Q000097:blood*; D005165:Factor V / Q000032:analysis / Q000276:immunology; D005169:Factor VIII / Q000032:analysis / Q000276:immunology; D005260:Female; D006474:Hemorrhagic Disorders / Q000097:blood / Q000209:etiology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007518:Isoantibodies / Q000097:blood; D008297:Male; D008875:Middle Aged; D010314:Partial Thromboplastin Time
chemical_list: D001323:Autoantibodies; D019774:Blood Coagulation Factor Inhibitors; D007074:Immunoglobulin G; D007518:Isoantibodies; D005165:Factor V; D005169:Factor VIII